147 related articles for article (PubMed ID: 30051646)
1. Excellent outcome of acute lymphoblastic leukaemia with TCF3-PBX1 rearrangement in Hong Kong.
Lin A; Cheng FWT; Chiang AKS; Luk CW; Li RCH; Ling ASC; Cheuk DKL; Chang KO; Ku D; Lee V; Ha SY; Li CK
Pediatr Blood Cancer; 2018 Dec; 65(12):e27346. PubMed ID: 30051646
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Jia M; Hu BF; Xu XJ; Zhang JY; Li SS; Tang YM
Curr Probl Cancer; 2021 Dec; 45(6):100758. PubMed ID: 34034913
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.
Pang L; Liang Y; Pan J; Wang JR; Chai YH; Zhao WL
Pediatr Hematol Oncol; 2015 Apr; 32(3):173-81. PubMed ID: 25551271
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Results of the Risk-Stratified Treatment of TCF3-PBX1-Positive Pediatric Acute Lymphoblastic Leukemia in China.
Wang Y; Xue YJ; Lu AD; Jia YP; Zuo YX; Zhang LP
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e137-e144. PubMed ID: 33221150
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Felice MS; Gallego MS; Alonso CN; Alfaro EM; Guitter MR; Bernasconi AR; Rubio PL; Zubizarreta PA; Rossi JG
Leuk Lymphoma; 2011 Jul; 52(7):1215-21. PubMed ID: 21534874
[TBL] [Abstract][Full Text] [Related]
6. Impact of TCF3 rearrangement on CNS relapse in egyptian pediatric acute lymphoblastic leukemia.
ElGendi HM; Abdelmaksoud AA; Eissa DG; Abusikkien SA
Pediatr Hematol Oncol; 2014 Oct; 31(7):638-46. PubMed ID: 25116187
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
Kager L; Lion T; Attarbaschi A; Koenig M; Strehl S; Haas OA; Dworzak MN; Schrappe M; Gadner H; Mann G;
Haematologica; 2007 Nov; 92(11):1561-4. PubMed ID: 18024406
[TBL] [Abstract][Full Text] [Related]
8. Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan.
Yen HJ; Chen SH; Chang TY; Yang CP; Lin DT; Hung IJ; Lin KH; Chen JS; Hsiao CC; Chang TT; Chang TK; Peng CT; Lin MT; Jaing TH; Liu HC; Jou ST; Lu MY; Cheng CN; Sheen JM; Chiou SS; Hung GY; Wu KH; Yeh TC; Wang SC; Chen RL; Chang HH; Yang YL; Chen SH; Cheng SN; Chang YH; Chen BW; Hsieh YL; Huang FL; Ho WL; Wang JL; Chang CY; Chao YH; Lin PC; Chen YC; Liao YM; Lin TH; Shih LY; Liang DC
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28436581
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
Paulsson K; Jonson T; Ora I; Olofsson T; Panagopoulos I; Johansson B
Br J Haematol; 2007 Jul; 138(2):196-201. PubMed ID: 17593026
[TBL] [Abstract][Full Text] [Related]
10. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
12. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Ribera J; Granada I; Morgades M; González T; Ciudad J; Such E; Calasanz MJ; Mercadal S; Coll R; González-Campos J; Tormo M; García-Cadenas I; Gil C; Cervera M; Barba P; Costa D; Ayala R; Bermúdez A; Orfao A; Ribera JM;
Br J Haematol; 2022 Feb; 196(3):670-675. PubMed ID: 34549416
[TBL] [Abstract][Full Text] [Related]
13. Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
Wan Y; Zhang H; Zhang L; Cai J; Yu J; Hu S; Fang Y; Gao J; Jiang H; Yang M; Liang C; Jin R; Tian X; Ju X; Hu Q; Jiang H; Li H; Wang N; Sun L; Leung AWK; Wu X; Wang J; Li CK; Yang J; Tang J; Shen S; Zhai X; Pui CH; Zhu X
Br J Haematol; 2022 Nov; 199(4):587-596. PubMed ID: 36114009
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
[TBL] [Abstract][Full Text] [Related]
15. Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion.
Rowsey RA; Smoley SA; Williamson CM; Vasmatzis G; Smadbeck JB; Ning Y; Greipp PT; Hoppman NL; Baughn LB; Ketterling RP; Peterson JF
Blood Cancer J; 2019 Oct; 9(10):81. PubMed ID: 31575852
[TBL] [Abstract][Full Text] [Related]
16. [A clinical and laboratory study of TCF3-PBX1 positive adult acute lymphoblastic leukemia.].
Zheng JF; Qiu HY; Pan JL; Cen JN; Wu YF; Zhang J; Wu DP; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2010 Jan; 31(1):16-20. PubMed ID: 20302770
[TBL] [Abstract][Full Text] [Related]
17. Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL97 study.
Li CK; Chik KW; Ha SY; Lee AC; Yuen HL; Ling SC; Lee V; Chan GC; Shing MM; Chan LC; Ng MH
Hong Kong Med J; 2006 Feb; 12(1):33-9. PubMed ID: 16495587
[TBL] [Abstract][Full Text] [Related]
18. Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG).
Asai D; Imamura T; Yamashita Y; Suenobu S; Moriya-Saito A; Hasegawa D; Deguchi T; Hashii Y; Endo M; Hatakeyama N; Kawasaki H; Hori H; Horibe K; Yumura-Yagi K; Hara J; Watanabe A; Kikuta A; Oda M; Sato A;
Cancer Med; 2014 Jun; 3(3):623-31. PubMed ID: 24578304
[TBL] [Abstract][Full Text] [Related]
19. [The Correlation of Minimal Residual Disease with Prognosis in TCF3-PBX1
Zhang L; Zou Y; Ai XF; Cao Z; Chen YM; Guo Y; Yang WY; Chen XJ; Wang SC; Liu XM; Ruan M; Liu TF; Liu F; Qi BQ; Chang LX; An WB; Ren YY; Li QH; Zhu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1831-1836. PubMed ID: 33283706
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
Eldfors S; Kuusanmäki H; Kontro M; Majumder MM; Parsons A; Edgren H; Pemovska T; Kallioniemi O; Wennerberg K; Gökbuget N; Burmeister T; Porkka K; Heckman CA
Leukemia; 2017 Jan; 31(1):51-57. PubMed ID: 27461063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
